Heart House Roundtables: Cardiovascular Clinical Research in the COVID-19 Era

Recently approved and emerging LDL-C lowering therapies represent exciting new opportunities for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD), but also present new questions and challenges for the cardiovascular community.

The LDL-C Lowering Therapies: The Changing Lipid Landscape Roundtable will address critical issues that continue to challenge the ability of clinicians to provide optimal care for patients with dyslipidemia. The goal of this Roundtable is to understand and address the role of new and emerging LDL-C lowering therapies in patients with ASCVD and high-risk primary prevention as well as those with statin-associated side effects.